-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The raw material medicine industry is one of the core directions of China's new pharmaceutical manufacturing, and it is of great significance in the development of the pharmaceutical industry
.
In recent years, with the continuous accelerated development of the pharmaceutical industry, China's API market is continuing to expand, and the concentration of the industry has also increased to a certain extent
.
It is worth noting that, as the API market continues to improve due to the development of the pharmaceutical industry and is ushering in a rapid increase in volume, a large number of API companies are expanding their production capacity to further meet the demand for APIs in the pharmaceutical market
.
Recently, Xingputai Biopharmaceutical Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, kicked off its construction in Taixing Economic Development Zone
.
It is understood that the Xingputai peptide API project was invested and constructed by Shanghai Shengpuzetai Pharmaceutical Technology Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, covering an area of 120 acres, and constructing an annual output of 1100 kilograms of high value-added peptide APIs, covering diabetes Polypeptide therapy fields such as therapy, anticoagulation, and varicose vein therapy
.
According to the plan, the project is scheduled to be completed in December 2022.
After reaching production capacity, it is expected to achieve annual sales revenue of 3 billion yuan and tax revenue of 420 million yuan
.
After completion, the industry expects that it will realize the industrialization of high-quality peptide APIs, and guide the pharmaceutical industry chain of Taixing Economic Development Zone to climb to the high end of the value chain
.
In October, Hubei Hendy Pharmaceutical Co.
, Ltd.
issued an announcement stating that it plans to list on the Shenzhen Stock Exchange’s Growth Enterprise Market and plans to issue no more than 60 million shares.
It plans to raise 1.
19 billion yuan and will be used for an annual production of 5,000 tons of ibuprofen raw materials.
, The project with an annual output of 1,200 tons of raw materials, an annual output of 12 tons of anti-tumor raw materials, and a supplementary working capital project
.
Among them, RMB 570 million was used for the project with an annual output of 5,000 tons of ibuprofen, RMB 290 million was used for the project with an annual output of 1,200 tons of raw materials, RMB 175 million was used for the project with an annual output of 12 tons of anti-tumor raw materials, and RMB 150 million was used for the project.
For supplementary liquidity projects
.
The prospectus shows that Hendy Pharmaceuticals is a company mainly engaged in the research and development, production and sales of chemical raw materials and preparation products
.
At present, it has formed a product system with non-steroidal anti-inflammatory raw materials as the core, and special raw materials such as cardiovascular and anti-tumor drugs as auxiliary products.
.
In September, Lewei Pharmaceutical GMP raw material medicine and intermediate production base project was signed in Lujiang County, Hefei City, Anhui Province
.
The total investment of the project is about 8 billion yuan, and the total land area is about 800 mu
.
The project is constructed in three phases.
After the third phase of the project is fully completed, it is expected to achieve an annual output value of about 12 billion yuan
.
Public information shows that Rovi Pharmaceuticals is a company specializing in industrialization outsourcing services for the innovative pharmaceutical industry.
The scope of services covers the process transformation of innovative pharmaceuticals from laboratory to industrialization, including process research and development and process optimization from pre-clinical to post-approval.
, Pilot-scale and large-scale production, etc.
At present, branches have been established in Beijing, Tianjin, Taizhou, Cangzhou, and the United States, including management centers, pilot-scale R&D platforms, non-GMP pilot-scale R&D services and production workshops, multi-functional cGMP production workshops, and Overseas branch
.
In general, in the face of good development opportunities in the API industry, many domestic API companies have begun to make forward-looking layouts and continue to expand their production capacity
.
It is worth noting that, in addition to this, the industry has also proposed that in order to better promote the development of the API industry, in the future, API companies need to further strengthen R&D investment in related fields and continuously enrich their product pipelines to achieve higher growth.
Enhance the company's core competitiveness and expand market share through mid- to long-term layout to drive steady growth in sales revenue and profits
.
.
In recent years, with the continuous accelerated development of the pharmaceutical industry, China's API market is continuing to expand, and the concentration of the industry has also increased to a certain extent
.
It is worth noting that, as the API market continues to improve due to the development of the pharmaceutical industry and is ushering in a rapid increase in volume, a large number of API companies are expanding their production capacity to further meet the demand for APIs in the pharmaceutical market
.
Recently, Xingputai Biopharmaceutical Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, kicked off its construction in Taixing Economic Development Zone
.
It is understood that the Xingputai peptide API project was invested and constructed by Shanghai Shengpuzetai Pharmaceutical Technology Co.
, Ltd.
, with a total investment of 1.
03 billion yuan, covering an area of 120 acres, and constructing an annual output of 1100 kilograms of high value-added peptide APIs, covering diabetes Polypeptide therapy fields such as therapy, anticoagulation, and varicose vein therapy
.
According to the plan, the project is scheduled to be completed in December 2022.
After reaching production capacity, it is expected to achieve annual sales revenue of 3 billion yuan and tax revenue of 420 million yuan
.
After completion, the industry expects that it will realize the industrialization of high-quality peptide APIs, and guide the pharmaceutical industry chain of Taixing Economic Development Zone to climb to the high end of the value chain
.
In October, Hubei Hendy Pharmaceutical Co.
, Ltd.
issued an announcement stating that it plans to list on the Shenzhen Stock Exchange’s Growth Enterprise Market and plans to issue no more than 60 million shares.
It plans to raise 1.
19 billion yuan and will be used for an annual production of 5,000 tons of ibuprofen raw materials.
, The project with an annual output of 1,200 tons of raw materials, an annual output of 12 tons of anti-tumor raw materials, and a supplementary working capital project
.
Among them, RMB 570 million was used for the project with an annual output of 5,000 tons of ibuprofen, RMB 290 million was used for the project with an annual output of 1,200 tons of raw materials, RMB 175 million was used for the project with an annual output of 12 tons of anti-tumor raw materials, and RMB 150 million was used for the project.
For supplementary liquidity projects
.
The prospectus shows that Hendy Pharmaceuticals is a company mainly engaged in the research and development, production and sales of chemical raw materials and preparation products
.
At present, it has formed a product system with non-steroidal anti-inflammatory raw materials as the core, and special raw materials such as cardiovascular and anti-tumor drugs as auxiliary products.
.
In September, Lewei Pharmaceutical GMP raw material medicine and intermediate production base project was signed in Lujiang County, Hefei City, Anhui Province
.
The total investment of the project is about 8 billion yuan, and the total land area is about 800 mu
.
The project is constructed in three phases.
After the third phase of the project is fully completed, it is expected to achieve an annual output value of about 12 billion yuan
.
Public information shows that Rovi Pharmaceuticals is a company specializing in industrialization outsourcing services for the innovative pharmaceutical industry.
The scope of services covers the process transformation of innovative pharmaceuticals from laboratory to industrialization, including process research and development and process optimization from pre-clinical to post-approval.
, Pilot-scale and large-scale production, etc.
At present, branches have been established in Beijing, Tianjin, Taizhou, Cangzhou, and the United States, including management centers, pilot-scale R&D platforms, non-GMP pilot-scale R&D services and production workshops, multi-functional cGMP production workshops, and Overseas branch
.
In general, in the face of good development opportunities in the API industry, many domestic API companies have begun to make forward-looking layouts and continue to expand their production capacity
.
It is worth noting that, in addition to this, the industry has also proposed that in order to better promote the development of the API industry, in the future, API companies need to further strengthen R&D investment in related fields and continuously enrich their product pipelines to achieve higher growth.
Enhance the company's core competitiveness and expand market share through mid- to long-term layout to drive steady growth in sales revenue and profits
.
